Posts
May 03 2023
Ensysce Biosciences, Inc. announced the closing of its Public Offering in the amount of $7,000,000. EG&S acted as counsel to the Placement Agent.
May 02 2023
cbdMD®, Inc., one of the nation’s leading CBD companies, announced the pricing of its previously announced underwritten public offering. Gross proceeds from the offering are expected to be approximately $2.8 million before deducting underwriting discounts, commissions, and estimated offering expenses. EGS acted as counsel to Maxim Group LLC, the sole book-running manager for the offering.
May 02 2023
Terran Orbital Corporation announced the closing of its Registered Direct offering in the amount of $37,100,000. EG&S acted as counsel to the Placement Agent.
May 01 2023
Daxor Corporation announced the closing of its Underwritten Public Offering in the amount of $4,000,000. EG&S acted as counsel to the Underwriter.
April 29 2023
ReShape Lifesciences Inc. announced the closing of its Registered Direct offering in the amount of $2,500,000. EG&S acted as counsel to the Placement Agent.
April 28 2023
Healthwell Acquisition Corp. I, a special purpose acquisition company, and Starton Therapeutics, Inc., a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced that they have entered into a definitive business combination agreement. EGS acted as counsel to Healthwell Acquisition Corp. I.
April 25 2023
Aditxt, Inc. announced the closing of its Registered Direct offering in the amount of $1,900,000. EG&S acted as counsel to the Placement Agent.
April 23 2023
U.S. GoldMining Inc. announced the closing of its Initial Public Offering in the amount of $20,000,000. EG&S acted as counsel to the Placement Agent.